Abstracts tagged "osteoclasts"

Abstract Number: 984 • 2019 ACR/ARP Annual Meeting
Important Role of CD11c+ Cells in Inflammatory Arthritis
Antonia Puchner¹, Elisabeth Simader ¹, Victoria Saferding ², Gerhard Kroenke ³, Rene Pfeifle ⁴, Daniel Aletaha ¹, Josef Smolen ¹ and Stephan Blueml ¹, ¹Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Austria, ⁴University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Dendritic cells (DCs) are important antigen presenting cells (APCs) and therefore they play an important role in bridging the innate and the adaptive immune…
Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Yannick Degboe ¹, Flavia Sunzini ¹, Iain McInnes ² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…
Abstract Number: 1969 • 2019 ACR/ARP Annual Meeting
FOXO1 Is Required for Human Osteoclast Differentiation
Sabarinadh Chilaka ¹, Yannick Degboe ¹, Iain McInnes ² and Carl Goodyear³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom., Glasgow, Scotland, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Dysregulation of osteoclast differentiation and function is a feature of inflammatory arthropathies (IA). Multiple genes and signalling pathways have been associated with regulation of…
Abstract Number: 1989 • 2019 ACR/ARP Annual Meeting
Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal
Aranzazu Mediero¹, Patricia Llamas-Granda ², Bruce Cronstein ³, Raquel Largo ⁴ and Gabriel Herrero-Beaumont ⁴, ¹IIS-FUNDACION JIMENEZ DIAZ, Madrid, Spain, ²IIS-FUNDACION JIMENEX DIAZ, Madrid, Spain, ³Department of Medicine, Division of Rheumatology NYUSoM, NYC, ⁴IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: Osteopenia and fragility fractures have been associated with HIV infection. Tenofovir, a common antiviral in HIV treatment, also leads to increases in bone catabolism…
Abstract Number: 2003 • 2019 ACR/ARP Annual Meeting
Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
JIAWEI XIE¹ and HUI DAI ¹, ¹Peking University, Beijing, China (People's Republic)
Background/Purpose: Anti-polygalacturonic acid antibody (PGA-Ab) is a new rheumatoid arthritis (RA)-related autoantibody first identified by our group. The sensitivity and specificity of PGA-Ab is even…
Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
Kazuhiro Yokota¹, Shinya Tanaka², Miyoko Sekikawa², Yoshimi Aizaki¹, Kojiro Sato¹, Hiromi Oda² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan
Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Yoshiya Tanaka¹, Tsutomu Takeuchi², Satoshi Soen³, Naoki Ishiguro⁴, Hisashi Yamanaka⁵, Toshiyuki Yoneda⁶, Sakae Tanaka⁷, Takaya Nitta⁸, Naoki Okubo⁹, Harry K. Genant¹⁰ and Désirée van der Heijde¹¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Kindai University Nara Hospital, Ikoma, Japan, ⁴Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Indiana University School of Medicine, Indianapolis, IN, ⁷Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, ⁸Daiichi Sankyo Co., Ltd., Tokyo, Japan, ⁹DaiichiSankyo CO., LTD., Tokyo, Japan, ¹⁰University of California, San Francisco, CA, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
Abstract Number: 1942 • 2017 ACR/ARHP Annual Meeting
CTLA4-Ig Directly Inhibits Osteoclast Generation from Human Peripheral Monocytes and Tumor Necrosis Factor α-Treated Inflammatory Monocytes
Katsuhiro Oi¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Yusuke Yoshida², Shintaro Hirata¹, Takaki Nojima³ and Eiji Sugiyama², ¹Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ³Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: CTLA-4 is a surface protein on T lymphocytes, which negatively regulates the co-stimulation process between antigen-presenting cells and T cells. CTLA-4 binds to monocytes…
Abstract Number: 329 • 2016 ACR/ARHP Annual Meeting
Explore the Possible Mechanisms of 1,25(OH)2D3 on the Formation of Osteoclasts in Rheumatoid Arthritis
Hong-yan WEN¹, Dan-dan LIU², Dan-dan WEI², Fang-fang ZHAO² and Xiao-feng LI², ¹Rheumatology, Shanxi Medical University, The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Shanxi Medical University, The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: In our previous study, several conclusions are reached like: (1) IL-22 can promote inflammation and osteoclast formation in the process of RA;(2) 1,25(OH)2D3 decreases serum IL-22 level in RA patients, and acts as a…
Abstract Number: 366 • 2016 ACR/ARHP Annual Meeting
Peripheral Osteoclastogensis Is Coming Back Along with Inflammation Twelve Months after Rituximab Therapy
Mie Jin Lim¹, Won Park², Seong-Ryul Kwon³ and Kyong-Hee Jung⁴, ¹Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ²Medicine/Rheumatology, IN-HA University Hospital, Choong-Gu Incheon, Korea, Republic of, ³Center for Rheumatism, Inha University Hospital, Incheon, South Korea, ⁴Hospital for Rheumatic Disease, Hanyang Univ Medical Center, Seoul, South Korea
Background/Purpose: We investigated change of bone turnover markers in peripheral blood before, 6 and 12 months after rituximab therapy in seropositive RA patients. Methods: Ten…
Abstract Number: 3097 • 2016 ACR/ARHP Annual Meeting
Osteoclast Precursor Frequency and Imaging Findings Associated with Arthritis Onset in a Psoriasis Longitudinal Cohort
Ralf G. Thiele¹, Yahui Grace Chiu², Francisco Tausk³, Bethany A. Marston⁴, Changyong Feng⁵, Gregory Dieudonne⁶, Vaseem Chengazi⁶, Sharon Moorehead⁷, Debbie Campbell⁷ and Christopher T. Ritchlin⁸, ¹Medicine, University of Rochester Medical Center, Rochester, NY, ²Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Dermatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Radiology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁸Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by an average of 10 years psoriatic arthritis (PsA) patients. Reports have demonstrated abnormal musculoskeletal imaging findings in psoriasis…
Abstract Number: 1737 • 2015 ACR/ARHP Annual Meeting
Increased Osteoclast Precursors with an Elevated DC-STAMP Expression May Identify Psoriasis Patients at Risk for Psoriatic Arthritis
Yahui Grace Chiu¹, Sutha Shanmugarajah², Dongge Li³, Megan Freiburger⁴, Sharon Moorehead⁵, Dafna Gladman⁶ and Christopher T. Ritchlin⁷, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Toronto Western Hospital, Toronto, ON, Canada, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Biology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁷Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop into psoriatic arthritis (PsA) within 10 years. This Ps-to-PsA transition paradigm provides a unique opportunity to recognize…
Abstract Number: 2569 • 2015 ACR/ARHP Annual Meeting
Regulation of SIRT1 Maybe a Perfect Strategy in Treatment of Rheumatoid Arthritis
Sang-Yeob Lee¹, Sung Won Lee², Won Tae Chung², Jae Ho Bae³, So Youn Park⁴ and Chi Dae Kim⁴, ¹Division of Rheumatology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea, ²Rheumatology, Dong-A University Hospital, Busan, South Korea, ³Biochemistry, Pusan national university, Yong -San, South Korea, ⁴Medical Research Center for Ischemic Tissue Regeneration, Pusan national university, Yong -San, South Korea
Background/Purpose: Monocyte may differentiate to osteoclasts in bone and macrophages in joint. so, blocking of monocyte differentiation maybe effective target in RA (rheumatoid arthritis) treatment.…
Abstract Number: 34 • 2014 ACR/ARHP Annual Meeting
Pro-Nerve Growth Factor (ProNGF) Stimulates Bone Growth By Stimulating Osteoblasts and Inhibiting Osteoclast Differentiation, an Explanation for Anti-NGF-Mediated Osteonecrosis; Prongf Is a Novel Therapeutic Target for Treatment of Osteonecrosis and Charcot’s Arthropathy
Aranzazu Mediero¹, Barbara Hempstead² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Neurotrophins (Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)) are initially synthesized as pro-neurotrophins (proNGF and proBDNF), which are hydrolyzed to produce the…
Abstract Number: 2340 • 2014 ACR/ARHP Annual Meeting
Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL-2Rγ^null Mice
Yosuke Nagasawa¹, Natsumi Ikumi², Takamasa Nozaki¹, Hirotake Inomata¹, Kenichi Imadome³, Noboru Kitamura¹, Mitsuhiro Iwata¹, Shigeyoshi Fujiwara⁴ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Department of Infectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan, ⁴Department of Iinfectious Diseases, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose Various studies of the relationship between Epstein-Barr virus (EBV) and rheumatoid arthritis (RA) have not produced convincing evidence. Many human viruses do not infect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].